Recombinant Cynomolgus Monkey B7-H2 Fc Chimera Protein, CF

When Recombinant Cynomolgus ICOS Fc Chimera (Catalog # 9736-CS) is coated at 0.5 μg/mL, Recombinant Cynomolgus B7-H2 Chimera (Catalog # 9900-B7) binds with an ED50 of 4-20 ng/mL.

2 μg/lane of Recombinant Cynomolgus Monkey B7‑H2 was resolved with SDS-PAGEunder reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 75-87 kDa and 150-170 kDa,respectively.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus Monkey B7-H2 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Cynomolgus Monkey ICOS Fc Chimera (Catalog # 9736-CS) is immobilized at 0.5 μg/mL (100 μL/well), the concentration of Recombinant Cynomolgus Monkey B7-H2 Fc Chimera that produces 50% of the optimal binding response is 4-20 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived cynomolgus monkey B7-H2 protein
  

  Cynomolgus Monkey B7‑H2 (Asp19-Thr256) Accession # XP_005548618	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: XP_005548618
• N-terminal Sequence: Asp19
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 53 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 75-87 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage:
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus Monkey B7-H2 Fc Chimera Protein, CF

• B7H2
• B7-H2
• B7H2B7 homolog 2
• B7-H2B7-related protein 1
• B7RP-1
• B7RP1B7-like protein Gl50
• B7RP-1LICOS
• CD275 antigen
• CD275
• GL50
• GL50transmembrane protein B7-H2 ICOS ligand
• ICOSL
• ICOS-L
• ICOSLG
• inducible T-cell co-stimulator ligand
• KIAA0653ICOS ligand

Background

B7-H2, also known as B7-related protein (B7RP1), ICOS Ligand, and CD275, is an approximately 60 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Cynomolgus B7-H2 is synthesized as a 306 amino acid (aa) precursor protein. Based on the similarity with human B7-H2, mature cynomolgus B7-H2 is predicted to consist of a 226 aa extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 21 aa cytoplasmic domain. Within the ECD, cynomolgus B7-H2 shares 94%, 50%, and 54% aa sequence identity with human, mouse, and rat B7-H2, respectively. B7-H2 is expressed on antigen presenting cells such as B cells, macrophages, monocytes, and dendritic cells (2-6). B7-H2 binds to ICOS on activated T cells, leading to both positive and negative effects on immune responses including its own down-regulation (2, 4, 7). Mouse and human B7-H2 exhibit cross-species binding to ICOS (3, 6). The B7-H2 interaction with ICOS is co-stimulatory for T cell proliferation as well as the development of B cells, plasma cells, follicular helper T cells (Tfh) and germinal centers (2-4, 8, 9). In human but not in mouse, B7-H2 additionally binds to CD28 and CTLA4, and its interaction with CD28 can co-stimulate both human and mouse naïve T cells and regulatory T cells (Treg) (6). B7-H2 contributes to the development of allergic asthma by enhancing Th2 biased immune responses, limiting Th17 responses, and promoting eosinophilic infiltration into the lung (8, 10, 11). Its activation of ICOS on Treg limits pulmonary inflammation and airway hyperresponsiveness, promotes the development of inhalational tolerance, and impairs anti-tumor immunity (5, 12, 13). In contrast, its ligation of ICOS on Tfh cells can increase the severity of autoimmune symptoms (9). A soluble form of human B7-H2 is elevated in the circulation of patients with active systemic lupus erythematosus (14). In the thyroid, B7-H2 is up-regulated on thyrocytes during inflammation and promotes their proliferation and production of thryoid hormones (15). B7-H2 and ICOS expressed on ILC2 cells. B7-H2/ICOS interaction promoted cytokine production and survival in ILC2 cells through STAT5, suggesting that B7-H2/ICOS signaling pathway is critically involved in ILC2 function and homeostasis (16).

1. Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.
2. Wang, S. et al. (2000) Blood 96:2808.
3. Yoshinaga, S.K. et al. (2000) Int. Immunol. 12:1439.
4. Yoshinaga, S.K. et al. (1999) Nature 402:827.
5. Faget, J. et al. (2012) Cancer Res. 72:6130.
6. Yao, S. et al. (2011) Immunity 32:729.
7. Watanabe, M. et al. (2008) J. Immunol. 180:5222.
8. Wong, S.-C. et al. (2003) Blood 102:1381.
9. Hu, Y.-L. et al. (2009) J. Immunol. 182:1421.
10. Kadkhoda, K. et al. (2010) J. Immunol. 184:3780.
11. Kadkhoda, K. et al. (2011) Int. Immunol. 23:239.
12. Gajewska, B.U. et al. (2005) J. Immunol. 174:3000.
13. Akbari, O. et al. (2002) Nat. Med. 8:1024.
14. Her, M. et al. (2009) Lupus 18:501.
15. Wang, F. et al. (2012) J. Clin. Immunol. 32:1253.
16. Maazi H. et al. (2015) Immunity.42:538.

Bioinformatics

• Uniprot:
  • XP_005548618()